- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02507765
Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
A Pilot Trial of Stereotactic Body Radiation Therapy (SBRT) to Induce Tumor Hyperemia in Combination With Transarterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To establish the feasibility of completing SBRT followed by TACE in a 2 day time period.
SECONDARY OBJECTIVES:
I. To determine acute tumor perfusion changes after SBRT using functional magnetic resonance imaging (MRI) (magnetic resonance [MR]-dynamic contrast enhanced [DCE]/perfusion weighted imaging [PWI], MR-diffusion, blood oxygen level dependent [BOLD] sequences).
II. To establish safety and tolerability of this regimen. III. To determine overall response rates (using modified Response Evaluation Criteria in Solid Tumors [RECIST] criteria), including objective response rate (partial response [PR] + complete response [CR]) and clinical benefit rate (stable disease [SD] + PR + CR) at 1, 3, and 6 months after TACE.
IV. To evaluate local control, progression-free survival, and overall survival at 1, 3, 6, 9, and 12 months after a single-dose of SBRT followed by TACE.
V. To correlate micro ribonucleic acid (miRNA) biomarkers with response and toxicity.
OUTLINE: This is a dose-escalation study of SBRT.
Patients undergo SBRT on day 1 and TACE on day 2.
After completion of study treatment, patients are followed up at 1-2 weeks and at 1, 3, 6, 9, 12, 18, and 24 months.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion listed below:
- Histologically confirmed
- Magnetic resonance imaging (MRI) or computerized tomography (CT) findings consistent with hepatocellular carcinoma
- Alpha fetoprotein (AFP) > 400 ng/mL AND evidence of at least one solid liver lesion > 2 cm regardless of specific imaging characteristics on CT or MRI
- Patients must be non-transplantable, unresectable, or medically inoperable and eligible for TACE as determined by a multi-disciplinary team
- Absolute neutrophil count >= 1.5 × 10^9/L
- Hemoglobin >= 9 g/dl
- Platelets >= 50,000/mm^3
- Prothrombin time (PT)/international normalized ratio (INR) and activated partial thromboplastin time (PTTa) =< 1.5
- Albumin >= 2.5 g/dL
- Alkaline phosphatase < 5 x upper limit of normal (ULN)
- Total bilirubin =< 2.0 mg/dL
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x ULN
- Creatinine =< 1.5 mg/dL and calculated creatinine clearance >= 60 mL/min or 24-hour urine creatinine clearance >= 60 mL/min
- Must have Childs-Pugh A or B liver disease
Patients must have no clinical signs of heart failure and meet New York Heart Association functional classification I or II defined as:
- Class I - patients with no limitation of activities; they suffer no symptoms from ordinary activities
- Class II - patients with slight, mild limitation of activity; they are comfortable with rest or with mild exertion
- Must have 1-3 liver lesions amenable to SBRT with tumor size < 15 cm (single lesion or sum)
- Must be able to undergo two MRI scans, one before study treatment begins and another shortly after SBRT
- Patients with extrahepatic disease, portal hypertension, or bilobar disease are allowed
- Normal renal function (creatinine < 1.5 mg/dL)
- Within 2 weeks of registration: patients must have vital signs, history/physical examination, laboratory studies (complete blood count [CBC] with differential, chemistries including liver function tests, AFP, creatinine clearance [CrCl] assessment, pregnancy test if needed)
- Life expectancy of at least 12 weeks in the opinion of investigator
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- Women of child-bearing potential (WOCBP) must have a negative pregnancy test within 14 days of the first administration of study treatment; urine human chorionic gonadotropin (HCG) is an acceptable pregnancy assessment
- Women/men of reproductive potential must be counseled on contraception/abstinence while receiving the study treatment
Exclusion Criteria:
- Childs-Pugh C liver function
- Major liver vascular invasion
- Prior radiation to the liver or other upper abdominal regions
- Must not have any evidence of bleeding diathesis or active gastrointestinal bleeding
- Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, or carcinoma in situ of the cervix; patients with a previous malignancy without evidence of disease for >= 3 years will be allowed to enter the trial
- History of active connective tissue disease (scleroderma)
- Subjects who are breast-feeding, or have a positive pregnancy test will be excluded from the study; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Medical contraindication to MR imaging (e.g. pacemakers, metallic implants, aneurysm clips, known contrast allergy to gadolinium contrast, pregnancy, nursing mothers, weight greater than 350 pounds)
Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the investigator; this could include severe, active co-morbidities such as:
- Uncontrolled cardiac disease (hypertension, unstable angina, myocardial infarction within last 6 months, uncontrolled congestive heart failure, cardiomyopathy with decreased ejection fraction)
- Acute bacterial or fungal infection requiring intravenous antibiotics at time of registration
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration
- Hepatic insufficiency resulting in jaundice and/or coagulation defects
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (SBRT, TACE)
Patients undergo SBRT on day 1 and TACE on day 2.
|
Correlative studies
Undergo SBRT
Other Names:
Undergo TACE
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of SBRT in combination with TACE, measured by the number of patients able to tolerate all study procedures
Time Frame: 2 days
|
Determined on the intent-to-treat principle.
Any treatment delivery difficulties that arise that could impede successful delivery of this therapy sequence will be evaluated.
The capability of the Ohio State University (OSU) system and communication between departments will be analyzed and deemed effective if it facilitates the successful treatment completion of all patients.
|
2 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in diffusion
Time Frame: Baseline to day 1 post-SBRT
|
Tested by comparing mean values pre- and post-SBRT using a paired t-test.
Should there be concern for outliers, the median for each metric will be determined and compared using a corresponding non-parametric procedure.
|
Baseline to day 1 post-SBRT
|
Change in hypoxia measurements
Time Frame: Baseline to day 1 post-SBRT
|
Tested by comparing mean values pre- and post-SBRT using a paired t-test.
Should there be concern for outliers, the median for each metric will be determined and compared using a corresponding non-parametric procedure.
|
Baseline to day 1 post-SBRT
|
Change in perfusion
Time Frame: Baseline to day 1 post-SBRT
|
Tested by comparing mean values pre- and post-SBRT using a paired t-test.
Should there be concern for outliers, the median for each metric will be determined and compared using a corresponding non-parametric procedure.
|
Baseline to day 1 post-SBRT
|
Incidence of toxicities
Time Frame: Up to 30 days
|
Includes measurement of grade 2-5 gastrointestinal symptoms, such as nausea, abdominal pain, hepatitis, enteritis, gastritis, bowel perforation, and fistula, as defined by Common Terminology Criteria for Adverse Events version 4.03.
|
Up to 30 days
|
Local control
Time Frame: Up to 12 months
|
Calculated using standard clinical follow-up with MRI imaging and labs.
|
Up to 12 months
|
Objective response rate (CR + PR) as measured by modified RECIST criteria version 1
Time Frame: Up to 6 months
|
Up to 6 months
|
|
Overall survival
Time Frame: Up to 12 months
|
Calculated using standard clinical follow-up with MRI imaging and labs.
Estimated using Kaplan-Meier analysis.
|
Up to 12 months
|
Progression-free survival
Time Frame: Up to 12 months
|
Calculated using standard clinical follow-up with MRI imaging and labs.
Estimated using Kaplan-Meier analysis.
|
Up to 12 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in BOLD response to oxygen breathing based on T2 contrast induced by deoxyhemoglobin serving as an endogenous contrast agent
Time Frame: Baseline to day 1 post-SBRT
|
Baseline to day 1 post-SBRT
|
Change in Kel (washout phase constant) values calculated from the DCE curve
Time Frame: Baseline to day 1 post-SBRT
|
Baseline to day 1 post-SBRT
|
Change in mean apparent diffusion coefficient generated from diffusion weighted images by using the b values
Time Frame: Baseline to day 1 post-SBRT
|
Baseline to day 1 post-SBRT
|
Change in miRNA expression
Time Frame: Baseline to up to 3 months
|
Baseline to up to 3 months
|
Change in plateau signal intensity calculated from the DCE curve
Time Frame: Baseline to day 1 post-SBRT
|
Baseline to day 1 post-SBRT
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Terence Williams, MD, PhD, Ohio State University Comprehensive Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSU-15032
- NCI-2015-00894 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Child-Pugh Class A
-
Stanford UniversityNational Cancer Institute (NCI)TerminatedRecurrent Hepatocellular Carcinoma | Child-Pugh Class A | Child-Pugh Class BUnited States, Japan
-
MedDay Pharmaceuticals SAEurofins OptimedTerminatedHealthy Volunteers | Hepatic Impairment of Moderate Child Pugh CategoryFrance, Hungary
-
RenJi HospitalCompletedPlatelet Count/Spleen Diameter Ratio | Child-Pugh ClassificationChina
-
Centre Hospitalier Universitaire DijonCompletedChild-Pugh A Hepatocellular CarcinomaFrance
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Memorial Sloan Kettering Cancer CenterUniversity of Southern California; Weill Medical College of Cornell University and other collaboratorsActive, not recruitingParents Who Have Lost a ChildUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Dana-Farber Cancer Institute; University of... and other collaboratorsActive, not recruitingParents Who Have Lost a Child to CancerUnited States
-
Public StrategiesChildren's Bureau - Administration for Children and Families; University of...CompletedParenting | Family Relations | Committed Couple Expecting a ChildUnited States
-
Nanjing PLA General HospitalUnknownImmune Function in Blood | Liver Function in Blood | Variation of Ascites | Characters of Quality of Life | Child-Pugh ScoreChina
-
Gazi UniversityNot yet recruitingCaregivers With a Child Followed up With a Cancer DiagnosisTurkey
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States